SINUS Medical Completes Over RMB 100 Million Series A Financing to Advance Innovative Cardiovascular Therapies

Jan 16, 2026 10:53 CST Updated 10:53

Sinus

Cardiovascular Consumables Developer

Biotech Transformation NetworkIn January 2026, Sinus (Suzhou Sinus Medical Technology Co., Ltd.) announced the completion of an A-round financing exceeding RMB 100 million.This round of financing was co-led by Guozhong Capital and Sherpa Healthcare Partners, with follow-up investments from Oriza Genesis, CD Capital, Zhongxin Capital, and Suzhou Industrial Park Science and Technology Innovation Fund.，To help Sinus innovate globally and benefit patients.

Sinus was founded in 2017.Is aA Global Innovative Medical Technology Company Focused on Major Cardiovascular Diseases. The current R&D pipeline focuses on heart failure and atrial fibrillation management, where the innovative therapy of septal radiofrequency ablation system for treating obstructive hypertrophic cardiomyopathy has received FDA Breakthrough Device Designation.

It is reported that the inspiration for the company name "Sinus" comes from the English word "SINUS" (SINUS is also the company's English name). The English definition of SINUS refers to sinus rhythm, which is considered by cardiovascular doctors to be the most beautiful melody. By naming the company this way, it signifies that the treatment solutions provided by the company can bring peace to all hearts.All patients with arrhythmia return to sinus rhythm and regain a healthy life, which is also the company's greatest wish and mission.

SinusCore Product "Interventricular Septum Radiofrequency Ablation System"Has entered the special review process for innovative medical devices in China and received FDA Breakthrough Device Designation, with its clinical value gaining authoritative recognition. The product adoptsPHASE Procedure (Percutaneous Helical Ablation of Septal Hypertrophy)By integrating mature pacing electrode with cold saline ablation technology, it achieves percutaneous, precise, and minimally invasive ventricular septal myocardial ablation, providing an innovative alternative to surgical operations and alcohol ablation for approximately 15 million patients globally suffering from obstructive hypertrophic cardiomyopathy. Currently, clinical enrollment has been initiated at multiple clinical institutions, including Beijing Anzhen Hospital affiliated with Capital Medical University and Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine. The product’s quality and clinical value have been authoritatively validated. This round of financing will fully promote the scaled clinical adoption and international cooperation of the product, accelerating the resolution of long-standing unmet clinical needs in this field, allowing safe and effective innovative therapies to benefit more patients.

Sinus Medical continues to gain favor in the capital market, having successfully completed multiple rounds of financing, with investors mostly being professional institutions focused on the medical technology field. This round of financing once again demonstrates the market's confidence in its "Safe and Effective, Simple and AccessibleA high level of recognition for innovative concepts. The company always adheres to the core drive of clinical value, and is committed to developing more locally original medical solutions originating from China through in-depth collaboration between medical and engineering fields, aiming to benefit a wide range of patients worldwide.

Source: Sinus, BioBAY

-End-

About Sinus

Central-med Club is established byShangji TransformationInitiated, and jointlyMultiple listed companies、Frontline Investment InstitutionsThe biomedicine industry service platform established by [entity name] follows the guidance of the "14th Five-Year Plan for Bioeconomy Development," aligning with the accelerating trend of global biotechnology evolution. It advances the innovation and industrial application of biotechnology, promotes the transfer and transformation of scientific and technological achievements through diversified services, supports the rapid growth of enterprises, facilitates specialized and innovative development, and assists specialized and innovative enterprises in going public—striving to build the most innovative and dynamic "High-Quality Development Empowerment Platform for Enterprises”。

Welcome to scan the code to join Sinus Academy